SEND V4.0 – What to expect and when to expect it Blog SEND V4.0 – What to expect and when to expect it April 24, 2025 As the Standard for Exchange of Nonclinical Data (SEND) continues to evolve…CertaraApril 24, 2025
Managing clinical metadata for your vendors, studies, and datasets Blog Managing clinical metadata for your vendors, studies, and datasets April 21, 2025 Clinical research is witnessing an evolution, driven by the increasing complexities of…Gilbert HunterApril 21, 2025
Using SDTM data to produce patient narratives Blog Using SDTM data to produce patient narratives In this blog, we look at how medical writers can use SDTM data produced by…CertaraApril 15, 2025
Exploring common CDISC ADaM conformance findings Blog Exploring common CDISC ADaM conformance findings March 27, 2025 ADaM data are required by the FDA and PMDA and accepted by…CertaraMarch 27, 2025
FDA requirements for providing datasets for nonclinical studies in SEND format Blog FDA requirements for providing datasets for nonclinical studies in SEND format March 19, 2025 The CDISC Standard for the Exchange of Nonclinical Data (SEND) provides the…Peggy ZornMarch 19, 2025
Gain nonclinical drug safety insights with real-time data analysis Blog Gain nonclinical drug safety insights with real-time data analysis February 24, 2025 Efficient drug development relies on informed decision-making. For toxicologists, having timely access…CertaraFebruary 24, 2025
The history of Pinnacle 21 Blog The history of Pinnacle 21 February 21, 2025 It was late 2007. Mad Men was the hottest show on TV.…CertaraFebruary 21, 2025
How to validate your clinical data using FDA validation rules Blog How to validate your clinical data using FDA validation rules January 30, 2025 For clinical data managers, understanding clinical data validation and applying FDA validation…CertaraJanuary 30, 2025
GlobalSubmit eCTD 4.0 Webinars On-Demand Webinar GlobalSubmit eCTD 4.0 Webinars The world of electronic regulatory submissions is about to change with the introduction of eCTD…CertaraDecember 3, 2024
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Poster Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi CertaraNovember 22, 2024